Harrow Health shares are trading higher after the company acquired US & Canadian rights to certain eye disease products and announced $60 million equity offering.
Portfolio Pulse from Benzinga Newsdesk
Harrow Health has acquired US & Canadian rights to certain eye disease products and announced a $60 million equity offering. This has led to an increase in the company's share price.
July 19, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow Health's acquisition of rights to eye disease products and equity offering could potentially increase the company's revenues and market share, positively impacting its stock price.
The acquisition of rights to eye disease products expands Harrow Health's product portfolio, potentially increasing its market share and revenues. The equity offering provides additional capital for the company, which could be used for further growth and expansion. These factors are likely to have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100